Northside Hospital, Inc. and Subsidiaries

Consolidated Financial Statements as of and for the Years Ended September 30, 2024 and 2023, and Independent Auditor's Report

Deloitte.

Deloitte & Touche LLP 1230 Peachtree Street NE Suite 3100 Atlanta, GA 30309-3574 USA

Tel:+1 855 335 0777 www.deloitte.com

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Northside Hospital, Inc. and Subsidiaries:

Opinion

We have audited the consolidated financial statements of Northside Hospital, Inc. (a Georgia not-forprofit corporation and a subsidiary of Northside Health Services, Inc.) and its subsidiaries ("Northside"), which comprise the consolidated balance sheets as of September 30, 2024 and 2023, and the related consolidated statements of operations, changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of Northside Hospital Inc. and its subsidiaries as of September 30, 2024 and 2023, and the results of its operations, the changes in its net assets, and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Northside and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Northside's ability to continue as a going concern for one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement

resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Northside's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Northside's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Deloitte + Touche LLP

January 14, 2025

CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2024 AND 2023 (In thousands)

ASSETS	2024	2023
CURRENT ASSETS: Cash and cash equivalents Patient accounts receivable—net Inventories Prepaid expenses and other assets	\$ 604,489 580,659 117,116 117,323	\$ 451,726 564,373 113,038 102,748
Total current assets	1,419,587	1,231,885
ASSETS WHOSE USE IS LIMITED—At fair value	988,164	778,439
PROPERTY AND EQUIPMENT—net	2,584,875	2,312,705
OTHER ASSETS: Right-of-use assets (Note 10) Goodwill Other intangible assets—net Pension plan assets Due from affiliates Other Total other assets	341,559 211,064 122,568 267,593 30,305 2,971 976,060	288,903 210,646 178,648 199,033 28,250 5,286 910,766
TOTAL	\$5,968,686	<u>\$ 5,233,795</u>

(Continued)

CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2024 AND 2023 (In thousands)

LIABILITIES AND NET ASSETS	2024	2023
CURRENT LIABILITIES: Current portion of finance lease obligations (Note 10) Current portion of operating lease obligations (Note 10) Accounts payable Accrued salaries and employee benefits Other accrued liabilities Current portion of self-insurance liabilities Total current liabilities	\$ 4,348 48,723 350,996 305,696 157,719 120,919 988,401	\$ 4,687 48,906 331,212 262,205 101,393 100,310 848,713
OTHER LONG-TERM LIABILITIES: Long-term self-insurance liabilities Operating lease obligations (Note 10) Real estate financing obligations Finance lease obligations—net of current portion (Note 10) Other long-term liabilities Total other long-term liabilities	441,940 295,377 140,442 50,463 12,425 940,647	390,555 241,599 144,280 54,811 10,133 841,378
Total liabilities	1,929,048	1,690,091
COMMITMENTS AND CONTINGENCIES (Notes 10 and 13)		
NET ASSETS: Without donor restrictions With donor restrictions Noncontrolling interest	4,001,656 4,176 33,806	3,510,347 5,482 27,875
Total net assets	4,039,638	3,543,704
TOTAL	<u>\$ 5,968,686</u>	<u>\$5,233,795</u>
See notes to consolidated financial statements.		(Concluded)

CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 (In thousands)

	2024	2023
REVENUES: Net patient service revenue	\$6,607,292	\$5,839,678
Other operating revenues	564,253	560,195
Total revenues	7,171,545	6,399,873
EXPENSES:		
Salaries and benefits	3,322,778	3,041,643
Supplies Professional fees	1,729,699 594,188	1,563,246 552,085
Depreciation and amortization	250,139	248,058
Other (Note 1)	1,045,995	905,841
Total expenses	6,942,799	6,310,873
OPERATING INCOME	228,746	89,000
INVESTMENT INCOME (Note 3)	218,345	118,550
OTHER COMPONENTS OF NET PERIODIC PENSION COSTS	23,950	15,718
REVENUES IN EXCESS OF EXPENSES	471,041	223,268
INCOME ATTRIBUTABLE TO NONCONTROLLING INTEREST	(18,625)	(16,235)
REVENUES IN EXCESS OF EXPENSES ATTRIBUTABLE TO NORTHSIDE HOSPITAL, INC. AND SUBSIDIARIES	<u>\$ 452,416</u>	<u>\$ 207,033</u>

See notes to consolidated financial statements.

CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 (In thousands)

	Net Assets without Donor Restrictions	Net Assets with Donor Restrictions	Noncontrolling Interest	Total
NET ASSETS—September 30, 2022	\$3,230,489	\$ 6,624	\$ 27,046	\$3,264,159
Revenues in excess of expenses	207,033	-	16,235	223,268
Other	(26,897)	(1,142)	(15,406)	(43,445)
Change in unrecognized pension costs	99,722			99,722
Change in net assets	279,858	(1,142)	829	279,545
NET ASSETS—September 30, 2023	3,510,347	5,482	27,875	3,543,704
Revenues in excess of expenses	452,416	-	18,625	471,041
Other	-	(1,306)	(12,694)	(14,000)
Change in unrecognized pension costs	38,893			38,893
Change in net assets	491,309	(1,306)	5,931	495,934
NET ASSETS—September 30, 2024	\$4,001,656	\$ 4,176	\$ 33,806	\$4,039,638

See notes to consolidated financial statements.

CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 (In thousands)

	2024	2023
CASH FLOWS FROM OPERATING ACTIVITIES:		
Change in net assets	<u>\$ 495,934</u>	\$ 279,545
Adjustments to reconcile changes in net assets to net cash provided by		
operating activities:		
Depreciation and amortization	250,139	248,058
Income on equity-method investments	(513)	(1,212)
Distributions from equity-method investments	314	2,992
Net realized and unrealized gains on investments	(190,557)	(90,439)
Change in unrecognized pension costs	(38,893)	(99,722)
Retirement plan expense in excess of current-year funding	(29,666)	(21,926)
Loss on impairment of intangible assets	53,922	-
Other	13,307	15,948
Changes in assets and liabilities:	(4.4.606)	FF 742
Patient accounts receivable	(14,686)	55,742
Inventories Propoid evenesses and other accests	(4,078)	(4,654)
Prepaid expenses and other assets	41,431	12,381
Accounts payable Accrued liabilities	77,190 (9,251)	(62,876) 57,025
Self-insurance liabilities	71,994	91,473
Sen-insurance magnifiles	71,554	91,475
Total adjustments	220,653	202,790
Net cash provided by operating activities	716,587	482,335
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of assets whose use is limited	(365,532)	(416,618)
Proceeds from disposal of assets whose use is limited	345,657	400,910
Acquisitions (Note 2)	(12,070)	(51,223)
Proceeds from sale of property and equipment	-	33
Purchase of property and equipment	(512,149)	(505,259)
Transactions with affiliates—net	(2,055)	(4,348)
Other	(605)	3,400
Net cash used in investing activities	(546,754)	(573,105)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Net proceeds from real estate financing transactions	-	565
Net repayment of current and long-term debt and capital leases	(4,376)	(9,311)
Other—net	(12,694)	(15,406)
Net cash used in by financing activities	(17,070)	(24,152)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	152,763	(114,922)
CASH AND CASH EQUIVALENTS—Beginning of year	451,726	566,648
CASH AND CASH EQUIVALENTS—End of year	\$ 604,489	\$ 451,726
	, 004,403	, 4 J1,/20

See notes to consolidated financial statements.